RR (incidence) and factor (quantity) of healthcare use in the DLCST groups compared with the reference group
| Total costs | Groups | RR | RR lower 95% CI | RR upper 95% CI | RR p value | Factor (F) | F lower 95% CI | F upper 95% CI | Factor p value | Cumulative effect |
| Total costs excl. direct cost of CT-screening programme | CONT | 1.008 | 0.994 | 1.022 | 0.284 | 1.468 | 1.325 | 1.627 | 0.000* | 1.479 |
| CT | 1.013 | 0.999 | 1.027 | 0.068 | 1.501 | 1.354 | 1.663 | 0.000* | 1.520 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Total costs incl. cost of CT-screening programme | CONT | 1.008 | 0.994 | 1.022 | 0.286 | 1.471 | 1.334 | 1.622 | 0.000* | 1.483 |
| CT | 1.012 | 0.999 | 1.026 | 0.073 | 1.585 | 1.437 | 1.747 | 0.000* | 1.604 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Secondary sector | ||||||||||
| Hospitalisation days | CONT | 1.137 | 1.000 | 1.293 | 0.050 | 0.989 | 0.856 | 1.144 | 0.884 | 1.125 |
| CT | 1.137 | 0.999 | 1.295 | 0.051 | 1.056 | 0.914 | 1.221 | 0.457 | 1.202 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Outpatient visits | CONT | 1.085 | 1.032 | 1.142 | 0.002* | 1.012 | 0.930 | 1.102 | 0.777 | 1.099 |
| CT | 1.065 | 1.012 | 1.121 | 0.016* | 1.046 | 0.961 | 1.139 | 0.301 | 1.114 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Emergency room contacts | CONT | 1.144 | 1.057 | 1.239 | 0.001* | 1.102 | 1.020 | 1.192 | 0.014* | 1.261 |
| CT | 1.144 | 1.057 | 1.239 | 0.001* | 1.110 | 1.026 | 1.200 | 0.009* | 1.270 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Surgical procedures | CONT | 1.065 | 0.975 | 1.163 | 0.163 | 1.024 | 1.098 | 1.098 | 0.511 | 1.090 |
| CT | 1.063 | 0.973 | 1.162 | 0.178 | 1.034 | 1.109 | 1.109 | 0.355 | 1.099 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Non-surgical procedures | CONT | 1.028 | 0.992 | 0.134 | 0.134 | 0.966 | 0.901 | 1.034 | 0.318 | 0.992 |
| CT | 1.020 | 0.984 | 0.278 | 0.278 | 0.96 | 0.896 | 1.028 | 0.244 | 0.979 | |
| REF | 1.000 | 1.000 | – | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Primary sector | ||||||||||
| GP contacts | CONT | 1.018 | 1.002 | 1.035 | 0.024 | 1.041 | 1.000 | 1.084 | 0.053 | 1.060 |
| CT | 1.025 | 1.010 | 1.041 | 0.002* | 1.035 | 0.994 | 1.078 | 0.094 | 1.062 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| GP costs | CONT | 1.021 | 1.005 | 1.037 | 0.009* | 1.052 | 1.013 | 1.093 | 0.009* | 1.074 |
| CT | 1.028 | 1.012 | 1.044 | 0.006* | 1.049 | 1.010 | 1.090 | 0.013* | 1.078 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Other specialist MD costs | CONT | 1.105 | 1.056 | 1.156 | 0.000* | 1.075 | 1.011 | 1.143 | 0.022 | 1.188 |
| CT | 1.094 | 1.045 | 1.145 | 0.000* | 1.072 | 1.008 | 1.141 | 0.027 | 1.173 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Psychologist costs | CONT | 1.073 | 0.667 | 1.727 | 0.772 | 0.987 | 0.795 | 1.226 | 0.906 | 1.059 |
| CT | 0.972 | 0.588 | 1.607 | 0.912 | 1.053 | 0.848 | 1.309 | 0.640 | 1.024 | |
| REF | 1.000 | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Physiotherapist costs | CONT | 1.163 | 1.036 | 0.011* | 1.107 | 1.107 | 0.968 | 1.266 | 0.139 | 1.287 |
| CT | 1.170 | 1.042 | 0.008* | 1.032 | 1.032 | 0.902 | 1.181 | 0.642 | 1.208 | |
| REF | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | 1.000 | – | 1.000 | |
| Prescription drug costs | CONT | 1.036 | 1.014 | 0.001* | 1.063 | 1.063 | 0.967 | 1.167 | 0.205 | 1.101 |
| CT | 1.041 | 1.019 | 0.000* | 1.044 | 1.044 | 0.950 | 1.147 | 0.371 | 1.087 | |
| REF | 1.000 | 1.000 | – | 1.000 | 1.000 | 1.000 | 1.000 | – | 1.000 |
Cumulative effect=relative risk × factor. After adjustments for multiple testing using the method of Benjamini-Hochberg the level of statistical significance was asserted at 0.0202.
CONT, control group from DLCST; CT, CT group from DLCST; DLCST, Danish Randomised Controlled Lung Cancer Screening Trial; GP, general practitioner; REF, Reference group; RR, relative risk.